Glial therapeutics represent a promising frontier in neurodegenerative disease drug development for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, targeting the non-neuronal cells of the brain (microglia, astrocytes, oligodendrocytes) that play critical roles in neurodegeneration. This analysis covers microglial modulators, TREM2 agonists/antagonists, complement inhibitors, astrocyte-targeted therapies, CSF1R inhibitors, and NLRP3 inhibitors.
Glial cells—particularly microglia and astrocytes—are increasingly recognized as key drivers of neurodegeneration:
- Microglia: The brain's resident immune cells; drive neuroinflammation via TREM2, complement, and cytokine signaling
- Astrocytes: Support neuronal metabolism; dysfunction leads to potassium buffering failure (AQP4) and neurotransmitter dysregulation
- Oligodendrocytes: Myelin-producing cells; dysfunction contributes to axonal degeneration
flowchart TD
A["Neurotoxic Glial State"] --> B["Chronic Neuroinflammation"]
A --> C["Failed Phagocytosis"]
A --> D["Metabolic Support Loss"]
B --> E["Neuronal Death"]
C --> E
D --> E
F["Glial Therapeutic Intervention"] --> G["TREM2 Modulation"]
F --> H["Complement Inhibition"]
F --> I["CSF1R Modulation"]
F --> J["NLRP3 Inhibition"]
G --> K["Restored Microglial Function"]
H --> K
I --> K
J --> K
K --> L["Reduced Neuroinflammation"]
L --> M["Neuroprotection"]
| Category |
Active Programs |
Phase I |
Phase II |
Phase III |
| TREM2 Modulators |
5 |
2 |
2 |
1 |
| Complement Inhibitors |
8 |
3 |
4 |
1 |
| CSF1R Inhibitors |
4 |
2 |
2 |
0 |
| NLRP3 Inhibitors |
6 |
2 |
3 |
1 |
| Astrocyte-Targeted |
3 |
1 |
2 |
0 |
- AL002 (Alector/AbbVie) - TREM2 agonist, Phase II for Alzheimer's disease
- AL003 (Alector) - TREM2 antibody, Phase I
- Lu AF87908 (Lundbeck) - TREM2 antibody, Phase I
- Avacopan (Chemocentryx/VistaGen) - C5aR antagonist, Phase III for vasculitis
- Pegcetacoplan (Apellis) - C3 inhibitor, Phase III for AMD
- Pexidartinib (Daiichi Sankyo) - CSF1R antagonist, approved for TGCT
- BLZ945 (Boehringer Ingelheim) - CSF1R antagonist, Phase I/II
- Dapansutrile (Olatec) - NLRP3 inhibitor, Phase II for COVID-19
- Inzomelid (Inflazome) - NLRP3 inhibitor, Phase I
| Dimension |
Score |
Rationale |
| Novelty |
8 |
Novel therapeutic approach targeting non-neuronal cells |
| Mechanistic Rationale |
9 |
Strong evidence for glial involvement in neurodegeneration |
| Root-Cause Coverage |
7 |
Targets neuroinflammation and glial dysfunction |
| Delivery Feasibility |
5 |
BBB remains challenge for some modalities |
| Safety Plausibility |
7 |
Glial modulation has acceptable safety profile |
| Combinability |
8 |
Highly complementary with neuronal targets |
| Biomarker Availability |
7 |
TREM2, Iba1, and cytokine biomarkers available |
| De-risking Path |
6 |
Multiple programs in clinical development |
| Multi-disease Potential |
9 |
AD, PD, ALS, MS - multiple indications |
| Patient Impact |
7 |
Addresses neuroinflammation as key driver |
Total: 71/100
- TREM2 agonist screening: Test existing TREM2 antibodies (AL002, AL003) in iPSC-derived microglia for phagocytosis enhancement
- Biomarker correlation: Measure CSF TREM2, YKL-40, and neurofilament levels in patients receiving glial modulators
- Combination testing: Test glial modulators combined with anti-amyloid or anti-tau therapeutics
- Patient stratification: Select patients based on microglial activation markers (PET, CSF)
- Dose-finding design: Start with low-dose TREM2 modulator and titrate based on biomarkers
- Combination protocol: Consider adding glial modulator to standard-of-care
- Alector/AbbVie: AL002 and AL003 programs - established partnership
- Boehringer Ingelheim: BLZ945 CSF1R program
- Apellis Pharmaceuticals: Complement platform (pegcetacoplan)
- Olatec Therapeutics: NLRP3 inhibitor pipeline
Glial therapeutic investments have increased significantly from $500M in 2019 to over $2.1B in 2024, representing a 4x increase in venture funding and pharma partnerships.
- Blood-brain barrier penetration - Many glial targets require CNS-penetrant compounds
- Biomarker development - TREM2 and microglial biomarkers needed for patient selection
- Combination approaches - Glial modulators + neuronal targets
- Genetic stratification - TREM2 variant carriers as enriched population
- Neuroinflammation — primary target
- Microglia Activation — disease-associated microglia
- Astrocyte Dysfunction — reactive astrocytes
- Oligodendrocyte Function — myelin maintenance
- Blood-Brain Barrier — neurovascular unit
- Neurovascular Coupling — glia-vessel interactions
- Microglia — immune surveillance
- Astrocytes — metabolic support
- Oligodendrocytes — myelination
- Pericytes — vascular function
- Neuroprotective Strategies — overall approach
- Anti-inflammatory Approaches — reduce gliosis
- Cell Therapy — glial cell transplantation
- Immunotherapy — modulate glial activation
| Phase |
Duration |
Key Milestones |
| Lead Optimization |
6-12 months |
Screen candidates, optimize PK/PD |
| Preclinical (IND-enabling) |
18-24 months |
GLP toxicology, efficacy in models, GMP manufacturing |
| IND-enabling studies |
12-18 months |
GLP toxicology, CMC, regulatory meetings |
| Phase I |
12-18 months |
Safety, dose-ranging in patients |
- Lead optimization: $3-6M
- Preclinical development: $10-18M
- IND-enabling studies: $8-15M
- Phase I trials: $15-25M
- Total to Phase I: $36-64M
- University of Pennsylvania — Dr. John Trojanowski
- Stanford University — Dr. Marion Buckwalter
- UCLA — Dr. Varghese John
- University of Michigan — Dr. Henry Paulsen
- Karolinska Institutet — Dr. Tomas M barek
- Biogen — Neuroscience pipeline
- Roche — CNS portfolio
- Merck — Neuroscience division
- Takeda — Neuroscience acquisitions
- AbbVie — CNS programs
| Risk |
Likelihood |
Impact |
Mitigation |
| Brain penetration failure |
Medium |
High |
Early PK/PD screening |
| Off-target effects |
Low |
Medium |
Selectivity profiling |
| Clinical trial recruitment |
Low |
Medium |
Multi-center design |
- Fast Track Designation: Possible
- Biomarker Development: Relevant biomarkers
- Accelerated Approval: Possible with biomarker endpoint